Efficacy of Short-Course vs Long-Course Antibiotic Therapy for Community-Acquired Pneumonia:A Systematic Review and Meta-Analysis
Not Applicable
- Conditions
- Community-acquired pneumonia
- Registration Number
- JPRN-UMIN000049959
- Lead Sponsor
- Japan Respiratory Society
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Pediatric patients.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prognosis, clinical efficacy, relapse of pneumonia, hospital days, adverse events, cost
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms differentiate short-course and long-course antibiotic therapies in community-acquired pneumonia?
How does short-course antibiotic therapy compare to standard-of-care long-course regimens in CAP patient outcomes?
Which biomarkers can predict response to short-course antibiotic therapy in CAP subtypes like atypical pneumonia?
What are the potential adverse events associated with short-course antibiotic therapy for CAP and how are they managed?
Are there any combination approaches or competitor drugs that enhance short-course antibiotic efficacy in CAP treatment?